Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Member of Medical Advisory Board & Independent Non-Executive Director John Tooke was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • May 01
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Member of Medical Advisory Board & Independent Non-Executive Director John Tooke was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 24
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Member of Medical Advisory Board & Independent Non-Executive Director John Tooke was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Nov 20
Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 8 million. Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 8 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 133,333,334
Price\Range: AUD 0.06
Discount Per Security: AUD 0.0036
Transaction Features: Subsequent Direct Listing Aankondiging • Aug 30
Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million. Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 120,206,872
Price\Range: AUD 0.024
Discount Per Security: AUD 0.00144
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 46,459,795
Price\Range: AUD 0.024
Discount Per Security: AUD 0.00144
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Reported Earnings • Aug 29
Full year 2025 earnings released: AU$0.007 loss per share (vs AU$0.032 loss in FY 2024) Full year 2025 results: AU$0.007 loss per share (improved from AU$0.032 loss in FY 2024). Revenue: AU$1.39m (down 37% from FY 2024). Net loss: AU$3.14m (loss narrowed 73% from FY 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Aankondiging • Aug 28
Emyria Limited, Annual General Meeting, Nov 13, 2025 Emyria Limited, Annual General Meeting, Nov 13, 2025. Location: level 2, 40 kings park road, west perth,western australia Australia Board Change • Aug 18
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Member of Medical Advisory Board & Independent Non-Executive Director John Tooke was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Jun 18
Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million. Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 120,206,872
Price\Range: AUD 0.024
Discount Per Security: AUD 0.00144
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 46,459,795
Price\Range: AUD 0.024
Discount Per Security: AUD 0.00144
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Board Change • Feb 04
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Chairman Greg Hutchinson was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Nov 27
Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.525 million. Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.525 million.
Security Name: Ordinary shares
Security Type: Common Stock
Securities Offered: 43,571,429
Price\Range: AUD 0.035
Discount Per Security: AUD 0.0021
Security Name: Ordinary shares
Security Type: Common Stock
Securities Offered: 28,571,429
Price\Range: AUD 0.035
Discount Per Security: AUD 0.0021
Transaction Features: Subsequent Direct Listing New Risk • Nov 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 23% per year over the past 5 years. Market cap is less than US$10m (AU$13.3m market cap, or US$8.60m). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (AU$2.2m revenue, or US$1.4m). Aankondiging • Oct 11
Emyria Limited, Annual General Meeting, Nov 12, 2024 Emyria Limited, Annual General Meeting, Nov 12, 2024. Location: at the offices of stantons international, level 2, 40 kings park road, west perth, wa, Australia Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023) Full year 2024 results: AU$0.032 loss per share (further deteriorated from AU$0.018 loss in FY 2023). Revenue: AU$2.20m (up 38% from FY 2023). Net loss: AU$11.5m (loss widened 123% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. New Risk • Aug 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Significant insider selling over the past 3 months (AU$672k sold). Revenue is less than US$5m (AU$1.9m revenue, or US$1.3m). Market cap is less than US$100m (AU$16.0m market cap, or US$10.5m). New Risk • Aug 07
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.40m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (AU$14.3m market cap, or US$9.40m). Minor Risks Shareholders have been diluted in the past year (33% increase in shares outstanding). Significant insider selling over the past 3 months (AU$672k sold). Revenue is less than US$5m (AU$1.9m revenue, or US$1.3m). Aankondiging • Apr 24
Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million. Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 39,600,000
Price\Range: AUD 0.05
Discount Per Security: AUD 0.003
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,400,000
Price\Range: AUD 0.05
Discount Per Security: AUD 0.003
Transaction Features: Subsequent Direct Listing New Risk • Feb 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$7.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.0m free cash flow). Earnings have declined by 21% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (AU$1.9m revenue, or US$1.3m). Market cap is less than US$100m (AU$17.2m market cap, or US$11.2m). Aankondiging • Nov 22
Emyria Limited Appoints Greg Hutchinson as Director Emyria Limited appointed Greg Hutchinson as director effective 21 November 2023. Aankondiging • Nov 15
Emyria Limited Announces Board Changes Emyria Limited announced that Dr. Alistair Vickery has retired from the Board and will shift his expertise from Board responsibilities to concentrate on clinical service expansion, particularly as Emyria advances its MDMA-assisted therapy programs. Dr. Stewart Washer will move to Non-Executive Chairman from Executive Chairman and his salary will move from $200,000 per annum to a total fee of $80,000 per annum and; Dr. Karen Smith to Non-Executive Director with a salary in line with all current Non-Executive Directors. All changes are effective immediately. Aankondiging • Nov 11
Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.678228 million. Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.678228 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,376,378
Price\Range: AUD 0.075
Transaction Features: Rights Offering Aankondiging • Sep 15
Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd. Emyria Limited (ASX:EMD) signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd for AUD 1.7 million in June 2023. The acquisition is valued at $1.7m payable in a combination of shares (76%) and cash (24%) (the Acquisition) and signifies a landmark moment for Emyria's mission to expand and improve mental health care. A cash payment of $400,000, to be paid on a deferred basis on 1 October 2023; And; the issue of 10,236,220 fully paid ordinary shares in Emyria, (Consideration Shares). The acquisition remains subject to the completion of conditions precedent. Emyria completing legal and other relevant due diligence on the Company to its satisfaction. Each Seller executing a voluntary restriction agreement for their respective portion of the Consideration Shares. Each Seller entering into a services agreement and consulting agreement with Emyria to supersede and replace any prior agreements between each Seller and the Company. The parties having obtained all other approvals, consents, or waivers of a third party required to implement the Acquisition. Emyria will raise AUD 3.1 million and use AUD 0.5 million to fund the acquisition. The transaction is expected to complete in Q1 FY24.
Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd on September 13, 2023. Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022) Full year 2023 results: AU$0.018 loss per share (improved from AU$0.027 loss in FY 2022). Revenue: AU$1.59m (down 13% from FY 2022). Net loss: AU$5.13m (loss narrowed 30% from FY 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Aankondiging • Aug 31
Emyria Limited, Annual General Meeting, Nov 16, 2023 Emyria Limited, Annual General Meeting, Nov 16, 2023, at 09:00 W. Australia Standard Time. Location: at the offices of Stantons International at Level 2, 40 Kings Park Road West Perth Western Australia Australia New Risk • Aug 29
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.2m free cash flow). Earnings have declined by 29% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding). Revenue is less than US$5m (AU$1.8m revenue, or US$1.1m). Market cap is less than US$100m (AU$25.3m market cap, or US$16.3m). Aankondiging • Aug 21
Emyria Limited Announces Strategic Board Transition Emyria Limited announced a strategic Board transition to bolster its clinical service growth in mental health, welcoming Dr. Mohit Kaushal as a Non-Executive Director. This change facilitates the transition of Matthew Callahan from a director of the Company to a unpaid advisory role where he will continue to provide strategic support for Emyria. Dr. Kaushal's appointment underscores Emyria's commitment to transforming mental health care by integrating state-of-the-art, multidisciplinary clinics alongside proprietary therapy development. As the global demand for mental health services rises, innovative new approaches - like psychedelic-assisted therapy - are gaining interest. The recent landmark decision by Australia to legalise the use of MDMA and psilocybin for PTSD and treatment-resistant depression, effective from July 1st, 2023 2 has created a unique opportunity for Emyria to harness its strengths in clinical service delivery, Real-World Data collection, and therapy development. Dr Kaushal's track record in scaling tech-integrated clinical services directly supports Emyria'. mission to lead the delivery and development of promising mental health interventions, globally. Dr. Mohit Kaushal's noteworthy affiliations encompass roles at Humedica (acquired by Optum Health), Rxante (acquired by Millennium), Change Healthcare (acquired by Emdeon), Universal American (NYSE:UAM) acquired by WellCare (NYSE:WCG), CitiusTech (acquired by Baring), Gravie, Insight Psychiatry, Wellframe (acquired by HealthEdge), Elation Health, The Oncology Institute (NASDAQ:TOI) and Oak Street Health. Oak Street Health, under Dr. Kaushal's stewardship culminated in a $10.6 Billion acquisition by CVS Health in 2023. Oak Street's technology-empowered, personalised care framework resonates with Emyria's vision for mental health. During his time in the Obama administration, Dr. Kaushal was a member of the White House Health IT task force; a cross agency team implementing the technology aspects of the Accountable Care Act (ACA) and testified to Congress on the application of technology and payment reform to the Medicare population. Dr. Kaushal also built and led the first dedicated health care team at the Federal Communications Commission, where his team initiated collaboration with the Food and Drug Administration (FDA) for the regulatory streamlining of converged telecommunications, data analytics and medical devices leading to the release of the mobile medical applications guidance by the FDA. In addition, his team reformed the Rural Healthcare fund to create the Healthcare Connect Fund, which aligned the funding mechanism with wider health care payment policy and technology reform. In addition, Dr. Kaushal is an Adjunct Professor at Stanford University within the Biomedical Data Science Department. Dr. Kaushal continues to be active within public policy and is aScholar in Residence at the Duke Margolis Center for Health Policy. He was previously a Visiting Scholar at the Brookings Institution. He has also been appointed to the FDASIA Workgroup of the Health IT Policy Committee and to the National Committee on Vital and Health Statistics, advising HHS on Data Access and Use. An ER physician by training, Dr. Kaushal also holds an MBA from Stanford and an MD with distinction as well as a BSc from Imperial College, London. New Risk • Aug 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.2m free cash flow). Earnings have declined by 29% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding). Revenue is less than US$5m (AU$1.8m revenue, or US$1.2m). Market cap is less than US$100m (AU$29.8m market cap, or US$19.5m). Aankondiging • Jul 04
Emyria Limited (ASX:EMD) signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million. Emyria Limited (ASX:EMD) signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million on June 3, 2023. The acquisition is valued at $1.7m payable in a combination of shares (76%) and cash (24%) (the Acquisition) and signifies a landmark moment for Emyria's mission to expand and improve mental health care. A cash payment of $400,000, to be paid on a deferred basis on 1 October 2023; And; the issue of 10,236,220 fully paid ordinary shares in Emyria, (Consideration Shares). The acquisition remains subject to the completion of conditions precedent. Emyria completing legal and other relevant due diligence on the Company to its satisfaction. Each Seller executing a voluntary restriction agreement for their respective portion of the Consideration Shares. Each Seller entering into a services agreement and consulting agreement with Emyria to supersede and replace any prior agreements between each Seller and the Company. The parties having obtained all other approvals, consents, or waivers of a third party required to implement the Acquisition. Aankondiging • Feb 13
Emyria Limited Secures Clinical-Grade MDMA Supply for Aust Patients Emyria Limited has secured a supply of clinical-grade MDMA for an initial cohort of Australian patients through Canadian manufacturer PharmAla, and facilitated by Mind Medicine Australia, when the rescheduling of MDMA comes into effect, July 1, 2023. The procurement of patient-ready, GMP-grade MDMA is highly challenging due to strict Good Manufacturing Practice standards, US supply quota restrictions and limited global manufacturers. PharmAla is one of the only companies able to export GMP-grade MDMA. Emyria intends to make the MDMA available to partner psychiatrists with Authorised Prescriber status or under ethics-approved clinical trials, and is actively collaborating with clinical partners to ensure their readiness for MDMA-assisted therapy by supporting clinician training and data monitoring. Australia will be one of the first countries to allow patient access to MDMA-assisted therapy. Securing a reliable, clinical-grade supply of MDMA poses significant challenges due to its highly regulated nature, requiring specialised knowledge, licences, and permissions from regulators and law enforcement. The supply agreement with PharmAla helps ensure Emyria's clinical partners will be ready to support safe and scalable MDMA-assisted therapy while complying with TGA restrictions regarding Authorised Prescriber status. The recent rescheduling of MDMA by the TGA following applications by Mind Medicine Australia also opens a pathway to registration and reimbursement for Emyria's MDMA-inspired compounds, which are being developed with the University of Western Australia for a range of neuropsychiatric disorders. Emyria is advancing its drug discovery program in Australia and the United States to identify novel, MDMA-like compounds with therapeutic potential, while collaborating with local clinical partners to improve patient access and ongoing research. Aankondiging • Feb 08
Emyria Limited Expands MDMA Programs Following Landmark TGA Decision Emyria Limited is well positioned to accelerate patient access to MDMA-assisted therapies following recent TGA regulation changes down-scheduling MDMA and psilocybin to Schedule 8 medicines from July 1st, 2023. A similar rescheduling of medicinal cannabis from Schedule 9 to Schedule 8 occurred in 2016. This protocol can now be adapted to support specialist psychiatrists meet the requirements for Authorised Prescriber status. This process requires an evaluation by a Human Research Ethics Committee. To date, Emerald Clinics (Emyria's clinical service subsidiary) has successfully applied for 16 Authorised Prescriber determinations relating to the provision of unregistered cannabinoid medicines to patients with unmet needs. In addition, Emyria and the University of Western Australia launched an MDMA-inspired drug discovery program. The partnership has now developed, screened and filed IP for over 140 proprietary, neurologically active and novel MDMA-like compounds with the potential to become registered treatments for a range of neuropsychiatric disorders and new psychedelic treatments. add psilocybin and MDMA to Schedule 8, permitting their use as Controlled Drugs only for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), respectively add entries in Appendix D to restrict access to the substances under Schedule 8: they can only be prescribed for the above conditions by specialist psychiatrists who have obtained approval to use the substances for treating these conditions from a human research ethics committee (HREC), and then been authorised by the TGA under the Authorised Prescriber Scheme to prescribe the substances for these conditions they can also be used in clinical trials into these conditions (they are currently only accessible for clinical trials as Schedule 9 substances)the possession of the substances as Schedule 8 drugs without authority will be illegal (for example, possession other than in accordance with a legal prescription). The rescheduling of MDMA opens a pathway to registration and reimbursement for MDMA and its analogues. Emyria will collaborate with clinical partners to improve patient access and ongoing research while continuing the drug discovery program in Australia and the United States to identify novel, MDMA-like compounds with the greatest therapeutic potential. Aankondiging • Jan 30
Emyria Limited Announces Commencement of First Dosing for Pivotal EMD-RX5 Phase 3 Trial Emyria Limited announced that the first patients have been successfully dosed in its Phase 3 clinical trial for EMD-RX5. This marks an important milestone in the development of EMD-RX5 as the first potential over-the-counter (OTC) treatment for the symptoms of psychological distress. The trial, which is being conducted nationwide across 9 trial sites, is designed to evaluate the safety and efficacy of EMD-RX5 in patients with symptoms of psychological distress such as mild anxiety and stress. The trial is expected to enrol and dose 300 patients in H1, 2023 and, pending clinically significant results, will support a submission to the TGA. A multi-site, parallel-arm, randomised, double blind, placebo-controlled study to investigate the effect of EMD-RX5 on symptoms of psychological distress in adults with chronic pain. 300 participants aged 18-70 with symptoms of stress and a background of chronic pain will be randomised to one month of treatment with either 50mg EMD-RX5, 150mg EMD-RX5 or matching placebo. To determine the effect of EMD-RX5 treatment on symptoms of psychological distress in participants with chronic pain through change in self-reported DASS-21 score from baseline to Week 4. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Member of Medical Advisory Board & Independent Non-Executive Director John Tooke was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 30
Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021) Full year 2022 results: AU$0.027 loss per share (down from AU$0.022 loss in FY 2021). Revenue: AU$1.82m (down 7.8% from FY 2021). Net loss: AU$7.33m (loss widened 49% from FY 2021). Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. 1 independent director (5 non-independent directors). Executive Chairman Stewart Washer is the most experienced director on the board, commencing their role in 2018. Member of Medical Advisory Board & Independent Non-Executive Director John Tooke was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 04
Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$1.98m (up 95% from FY 2020). Net loss: AU$4.91m (loss narrowed 6.3% from FY 2020). Reported Earnings • Sep 02
Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$1.98m (up 95% from FY 2020). Net loss: AU$4.91m (loss narrowed 6.3% from FY 2020). Reported Earnings • Feb 25
First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$1.15m (up 165% from 1H 2020). Net loss: AU$2.07m (loss narrowed 3.2% from 1H 2020). Is New 90 Day High Low • Feb 15
New 90-day high: AU$0.23 The company is up 222% from its price of AU$0.073 on 13 November 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 1.0% over the same period. Recent Insider Transactions • Nov 17
Executive Chairman recently bought AU$61k worth of stock On the 12th of November, Stewart Washer bought around 775k shares on-market at roughly AU$0.079 per share. This was the largest purchase by an insider in the last 3 months. Stewart has been a buyer over the last 12 months, purchasing a net total of AU$108k worth in shares. 